APOB and Obesity: Future research should prioritize HF populations with high residual metabolic risk, including patients with HFrEF and coexisting diabetes, HFpEF with obesity or metabolic syndrome, and individuals with persistently elevated ApoB or triglyceride-rich lipoproteins despite guideline-directed therapy.